T Shimada1, K Kojima, K Yoshiura, H Hiraishi, A Terano. 1. Department of Gastroenterology, Dokkyo University School of Medicine, Mibu, Tochigi 321-0293, Japan. tshimada@dokkyomed.ac.jp
Abstract
BACKGROUND: Involvement of peroxisome proliferator activated receptor gamma (PPARgamma) in the growth response of colon cancer cells has been suggested. AIMS: To investigate the characteristics of PPARgamma induced apoptosis in colon cancer cells. METHODS: The effects of ligands for each of the PPAR subtypes (alpha, delta, and gamma) on DNA synthesis and cell viability were examined in HT-29 colon cancer cells. Modulation of apoptosis related gene expression by PPARgamma ligands was screened with cDNA arrays, and the results were confirmed by quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis. RESULTS: PPARalpha, PPARdelta, and PPARgamma were all expressed in HT-29 cells. PPARgamma ligands, 15-deoxy-delta(12,)(14)-prostaglandin J2 (15d-PGJ2) and troglitazone (TGZ), suppressed DNA synthesis of HT-29 cells whereas ligands for PPARalpha and PPARdelta had no significant effects. Both 15d-PGJ2 and TGZ induced HT-29 cell death in a dose dependent manner which was associated with an increase in fragmented DNA and was sensitive to a caspase inhibitor. Among several genes selected by cDNA array screening, quantitative RT-PCR analysis confirmed downregulation of c-myc expression and upregulation of c-jun and gadd153 expression by 15d-PGJ2 and TGZ. PPARgamma induced apoptosis was antagonised by the presence of serum in the culture medium, and interaction between PPARgamma signalling and cell survival signalling through the phosphatidylinositol 3-kinase pathway was suggested. CONCLUSIONS: As c-myc is an important target gene of the adenomatous polyposis coli (APC)/beta-catenin and/or APC/gamma-catenin pathway, activation of PPARgamma signalling appears to compensate for deregulated c-myc expression caused by mutated APC. The present results suggest the potential usefulness of PPARgamma ligands for chemoprevention and treatment of colon cancers.
BACKGROUND: Involvement of peroxisome proliferator activated receptor gamma (PPARgamma) in the growth response of colon cancer cells has been suggested. AIMS: To investigate the characteristics of PPARgamma induced apoptosis in colon cancer cells. METHODS: The effects of ligands for each of the PPAR subtypes (alpha, delta, and gamma) on DNA synthesis and cell viability were examined in HT-29 colon cancer cells. Modulation of apoptosis related gene expression by PPARgamma ligands was screened with cDNA arrays, and the results were confirmed by quantitative reverse transcription-polymerase chain reaction (RT-PCR) analysis. RESULTS:PPARalpha, PPARdelta, and PPARgamma were all expressed in HT-29 cells. PPARgamma ligands, 15-deoxy-delta(12,)(14)-prostaglandin J2 (15d-PGJ2) and troglitazone (TGZ), suppressed DNA synthesis of HT-29 cells whereas ligands for PPARalpha and PPARdelta had no significant effects. Both 15d-PGJ2 and TGZ induced HT-29 cell death in a dose dependent manner which was associated with an increase in fragmented DNA and was sensitive to a caspase inhibitor. Among several genes selected by cDNA array screening, quantitative RT-PCR analysis confirmed downregulation of c-myc expression and upregulation of c-jun and gadd153 expression by 15d-PGJ2 and TGZ. PPARgamma induced apoptosis was antagonised by the presence of serum in the culture medium, and interaction between PPARgamma signalling and cell survival signalling through the phosphatidylinositol 3-kinase pathway was suggested. CONCLUSIONS: As c-myc is an important target gene of the adenomatous polyposis coli (APC)/beta-catenin and/or APC/gamma-catenin pathway, activation of PPARgamma signalling appears to compensate for deregulated c-myc expression caused by mutated APC. The present results suggest the potential usefulness of PPARgamma ligands for chemoprevention and treatment of colon cancers.
Authors: B Rubinfeld; B Souza; I Albert; O Müller; S H Chamberlain; F R Masiarz; S Munemitsu; P Polakis Journal: Science Date: 1993-12-10 Impact factor: 47.728
Authors: Jie Zhou; Wei Zhang; Bing Liang; Mathew C Casimiro; Diana Whitaker-Menezes; Min Wang; Michael P Lisanti; Susan Lanza-Jacoby; Richard G Pestell; Chenguang Wang Journal: Int J Biochem Cell Biol Date: 2009-06-26 Impact factor: 5.085
Authors: Kiyoshi Yamaguchi; Maria Cekanova; Michael F McEntee; Joo-Heon Yoon; Susan M Fischer; Ingrid B Renes; Isabelle Van Seuningen; Seung Joon Baek Journal: Mol Cancer Ther Date: 2008-09 Impact factor: 6.261
Authors: Débora Sinner; Jennifer J Kordich; Jason R Spence; Robert Opoka; Scott Rankin; Suh-Chin J Lin; Diva Jonatan; Aaron M Zorn; James M Wells Journal: Mol Cell Biol Date: 2007-09-17 Impact factor: 4.272
Authors: Nkechi Ichite; Mahavir B Chougule; Tanise Jackson; Suniket V Fulzele; Stephen Safe; Mandip Singh Journal: Clin Cancer Res Date: 2009-01-15 Impact factor: 12.531